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Myocardium-derived angiopoietin-1 is essential for
coronary vein formation in the developing heart
Yoh Arita1, Yoshikazu Nakaoka1,2, Taichi Matsunaga3, Hiroyasu Kidoya4, Kohei Yamamizu3, Yuichiro Arima5,
Takahiro Kataoka-Hashimoto1, Kuniyasu Ikeoka1, Taku Yasui1, Takeshi Masaki1, Kaori Yamamoto1, Kaori Higuchi1,
Jin-Sung Park6, Manabu Shirai7, Koichi Nishiyama5, Hiroyuki Yamagishi8, Kinya Otsu9, Hiroki Kurihara5,
Takashi Minami10, Keiko Yamauchi-Takihara1, Gou Y. Koh6, Naoki Mochizuki11, Nobuyuki Takakura4,
Yasushi Sakata1, Jun K. Yamashita3,12 & Issei Komuro13,14
The origin and developmental mechanisms underlying coronary vessels are not fully
elucidated. Here we show that myocardium-derived angiopoietin-1 (Ang1) is essential for
coronary vein formation in the developing heart. Cardiomyocyte-specific Ang1 deletion results
in defective formation of the subepicardial coronary veins, but had no significant effect on the
formation of intramyocardial coronary arteries. The endothelial cells (ECs) of the sinus
venosus (SV) are heterogeneous population, composed of APJ-positive and APJ-negative
ECs. Among these, the APJ-negative ECs migrate from the SV into the atrial and ventricular
myocardium in Ang1-dependent manner. In addition, Ang1 may positively regulate venous
differentiation of the subepicardial APJ-negative ECs in the heart. Consistently, in vitro
experiments show that Ang1 indeed promotes venous differentiation of the immature ECs.
Collectively, our results indicate that myocardial Ang1 positively regulates coronary vein
formation presumably by promoting the proliferation, migration and differentiation of
immature ECs derived from the SV.
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A
s the heart develops and the chamber walls thicken during
embryonic development, passive diffusion of oxygen and
nutrients is replaced by a vascular plexus, which is
remodelled and expands to form a mature coronary vascular
system1,2. The coronary arteries and veins ensure the continued
development of the heart and progressively increase cardiac
output towards birth. Elucidating the cellular and molecular
signals involved in vascularizing the embryonic heart would
provide significant insights into adult heart disease and tissue
regeneration. However, many aspects of the developmental
origins of coronary endothelial cells (ECs) and the specific
signals determining their fate have not been fully elucidated to
date2,3.
The heart is arranged in three layers: the endocardium,
myocardium and epicardium. The epicardium is the outermost
layer and is derived from the proepicardium located outside, but
close to the heart. The myocardium is the central layer, within
which the coronary vasculature develops. It is unclear whether
proepicardium/epicardial cells contribute significantly to coron-
ary EC formation in mammals, although some coronary ECs in
avian species are derived from proepicardial cells4–6. However,
more recent studies in mammals demonstrated that epicardial
cells generate coronary vascular smooth muscle cells but not
coronary ECs7,8. A recent report showed that the coronary vessels
in mammals are primarily derived from a common origin, the
differentiated venous ECs in the sinus venosus (SV), a major vein
located just above the developing liver that returns blood to the
embryonic heart9. According to that report, the sprouting venous
ECs dedifferentiate when they migrate over or invade the
myocardium. The intramyocardial invading ECs redifferentiate
into arteries, whereas the ECs proceeding along the subepicardial
layer of the heart redifferentiate into veins9. Another recent study
reported that the Semaphorin3D/Scleraxis lineage-traced
proepicardial cells, which traverse through SV endothelium en
route to the heart and/or transiently contribute to the
endocardium, differentiate into the coronary ECs10. A more
recent report suggested that endocardial ECs generate the
endothelium of coronary arteries through myocardial–
endothelial signalling by vascular endothelial growth factor-A
(VEGF-A) and vascular endothelial growth factor receptor 2
(VEGFR2)11. These findings suggest that coronary arteries and
veins have distinct origins and are formed by different molecular
mechanisms. Especially, the molecular mechanisms of coronary
vein formation have been elusive to date.
Angiopoietin-1 (Ang1) is a member of the angiopoietin family
of growth factors and is a major ligand for Tie2, a tyrosine kinase
receptor primarily expressed on ECs12,13. Ang1/Tie2 signalling is
required for EC quiescence, pericyte recruitment and the
formation of stable vessels12. The Ang1/Tie2 signalling pathway
is critical for normal development, since conventional Ang1 or
Tie2 knockout mice exhibit embryonic lethality between E9.5 and
E12.5, with similar abnormal vascular phenotypes and loss of
heart trabeculation14,15. We previously found that neuregulin-
1(NRG-1)/ErbB signalling is essential for cardiac homeostasis
presumably via Ang1 secreted from cardiomyocytes16. Thus, we
investigated the role of myocardial-derived Ang1 in coronary
vessel formation and cardiac homeostasis by creating
cardiomyocyte-specific Ang1-knockout mice.
In the present study, we show that myocardium-derived Ang1
is indispensable for coronary vein formation in the developing
heart. Cardiomyocyte-specific Ang1 deletion results in defective
formation of the subepicardial coronary veins, but does not affect
the formation of the intramyocardial coronary arteries. The ECs
of the SV consist of two heterogeneous populations, namely APJ-
positive and APJ-negative ECs. Among these, the APJ-negative
ECs migrate from the SV into the atrial and ventricular
myocardium in Ang1-dependent fashion. In addition, Ang1
promotes venous differentiation of the subepicardial APJ-negative
ECs in the heart. Furthermore, in vitro experiments using the
Flk1-positive immature endothelial progenitor cells demonstrate
that Ang1 indeed promotes venous differentiation. Taken
together, these findings suggest that myocardial Ang1 has an
essential role in coronary vein formation presumably by
promoting the proliferation, migration and differentiation of
immature ECs derived from the SV.
Results
Myocardial deletion of Ang1 results in embryonic lethality. We
hypothesized that myocardium-derived Ang1 is essential for heart
development by mediating coronary vessel formation. To test this
hypothesis, we generated cardiomyocyte-specific Ang1-knockout
(Ang1CKO) mice using the Cre-loxP system. We created an
Ang1flox allele by introducing two loxP sites into introns flanking
exon 1, which encodes part of the signal sequence17. To generate
Ang1CKO mice, we crossed Ang1flox/flox mice with a-MHC-Cre
transgenic mice16. We confirmed the expected genetic
recombination at the Ang1 locus in the heart, but not in the
head of Ang1CKO (Ang1flox/flox; a-MHC-Cre) embryos
(Supplementary Fig. 1a). We also confirmed that Ang1 mRNA
was ablated from the ventricles of Ang1CKO embryos compared
with that of control (Ang1flox/flox) embryos by whole-mount
in situ hybridization (Supplementary Fig. 1b)18. In addition, Ang1
mRNA expression was significantly reduced in the hearts of
Ang1CKO embryos compared with those of control embryos at
E8.5-E10.5 as assessed by quantitative reverse transcription –PCR
(qRT–PCR; Supplementary Fig. 1c). Consistently, we confirmed
that the Cre-mediated recombination at E8.5 and E9.5 through
crossing a-MHC-Cre mice with enhanced GFP reporter mice
(CAG-CAT-EGFP mice) (Supplementary Fig. 1d). No live
Ang1CKO mice were obtained, and Ang1CKO embryos died in
uterus between E12.5 and E14.5, slightly later than conventional
Ang1-knockout (Ang1KO) mice, which die at E12.5
(Supplementary Table 1)15,19.
Ang1CKO embryos show defects in coronary vein formation.
To examine the effect of myocardial deletion of Ang1 on the
coronary vessel formation, we performed a histological analysis of
the hearts of Ang1CKO embryos. Whole-mount CD31-immu-
nostaining revealed that Ang1CKO embryos exhibited impaired
subepicardial coronary vessel remodelling compared with control
embryos (Fig. 1a–d, Supplementary Fig. 2a–d). The whole-mount
stained samples were then sectioned for analysis. The sub-
epicardial CD31-positive vessel formation was specifically
disturbed in Ang1CKO embryos (Fig. 1e,f), whereas the intra-
myocardial CD31-positive vessel formation was almost similar in
control and Ang1CKO embryos (Fig. 1e,f,h). Although the sub-
epicardial CD31-positive vessels were detected uniformly from
the dorsal to ventral side in the ventricles of control embryos
(Fig. 1e), the number of subepicardial CD31-positive vessels
gradually decreased from the dorsal (Fig. 1f, area 1) to ventral side
(Fig. 1f, area 3) in the ventricles of Ang1CKO embryos. The
number of subepicardial CD31-positive coronary vessels in the
transverse section containing the inflow-tract area in Ang1CKO
embryos was indeed smaller by 57% than that of control (Fig. 1g),
indicating that the cardiomyocyte-specific deletion of Ang1
resulted in the impaired formation of subepicardial CD31-posi-
tive coronary vessels in the heart.
The subepicardial and intramyocardial CD31-positive vessels
are reported to give rise to the coronary veins and arteries,
respectively9,20. Thus, our findings suggest that the
cardiomyocyte-specific deletion of Ang1 may lead to defective
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formation of the subepicardial coronary veins. To characterize the
lost vessels in the hearts of Ang1CKO embryos, we examined
the expression of APJ, which is confined to the veins, by
whole-mount immunostaining21,22. Intriguingly, APJ-positive
subepicardial venous vessels were observed in both atria and
ventricles of control embryos, but not in those of Ang1CKO
embryos (Fig. 2a–d, Supplementary Fig. 3a,b). Analysis of the
sectioned samples clearly revealed subepicardial APJ-positive
vessel structures in the control but not in the Ang1CKO embryos
(Fig. 2e–h, Supplementary Fig. 3c,d), suggesting that
cardiomyocyte-derived Ang1 is required for the formation of
subepicardial APJ-positive mature coronary veins.
To examine the expression of Eph receptor B4 (EphB4),
another venous endothelial marker, in the Ang1CKO embryos,
we created Ang1flox/flox; a-MHC-Cre(þ ); EphB4 tau-lacZ(þ )
by crossing Ang1þ /flox; a-MHC-Cre-TG mice with EphB4
tau-lacZ knockin mice, which express the lacZ reporter gene in
the venous ECs23. EphB4-lacZ-positive signals were observed in
the subepicardial region of the hearts of control embryos at E13.0,
but not in those of Ang1CKO embryos (Fig. 2i–l, Supplementary
Fig. 3e–h).
Chicken ovalbumin upstream promoter-transcription factor
II (COUP-TFII), is reported to be a critical transcription factor
for the venous identity of ECs24,25. In situ hybridization revealed
that the expression of COUP-TFII is observed in the
subepicardial region of the hearts of control embryos at E13.5,
but not in those of Ang1CKO embryos (Fig. 2m–p). The
numbers of subepicardial differentiated coronary veins
identified by APJ-positive vessels, EphB4-lacZ-positive vessels
and COUP-TFII-positive vessels in Ang1CKO embryos were
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Figure 1 | Myocardial Ang1 is crucial for subepicardial coronary vessel formation. (a–d) Whole-mount immunostaining of embryonic hearts at E14.0
with anti-CD31 antibody. Myocardial Ang1 was required for subepicardial CD31-positive vessel remodelling (a,b: arrowheads in magnified image of inset).
The CD31-positive vessel formation was impaired in the ventricles of Ang1CKO embryos (c,d: arrowheads in magnified image of inset). (e,f) Sectioned
analysis of the whole-mount immunostained embryonic heart. Subepicardial CD31-positive vessels were detected uniformly in all the sections from
control embryo ventricles (e), whereas the density of subepicardial CD31-positive vessels decreased gradually from the dorsal (area 1) to the ventral side
(area 3) in Ang1CKO embryos (f). Arrows and arrowheads indicate the intramyocardial CD31-positive vessels and subepicardial CD31-positive vessels,
respectively. Area 1, dorsal side; area 2, lateral side; area 3, ventral side of the ventricles. (g,h) Quantification of the number of subepicardial and
intramyocardial CD31-positive vessels in the transverse section including inflow-tract of ventricle from E14.0 (n¼ 3). Scale bars, 400 mm in a,c; 100mm in
b,d; 200mm in e,f; and 50mm in magnified images of insets 1–3. LV, left ventricle; RV, right ventricle. Values are shown as means±s.e.m. for three separate
experiments. Student’s t-test was used to analyse differences. **Po0.01 compared with control. NS, not significant.
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reduced by 84–89% compared with those of control embryos
(Fig. 2q–s). In addition, the quantification revealed that the
number of subepicardial mature coronary veins positive for the
above venous markers in the ventricles was much less than that
of subepicardial immature CD31-positive vessels. Taken
together, these findings suggest that cardiomyocyte-specific
deletion of Ang1 impairs the formation of subepicardial
coronary veins.
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Figure 2 | Myocardial Ang1 is essential for coronary vein formation. (a–d) Whole-mount immunostaining of embryonic hearts with anti-APJ antibody.
APJ-positive coronary veins were observed on the surfaces of both the RA (a, arrowheads) and RV (c, arrowheads) of control embryos, but not on the
RA (b) or RV (d) of Ang1CKO embryos. (e–h) Sectioned analyses of the whole-mount immunostained embryonic hearts revealed subepicardial APJ-
positive coronary veins with vessel-like structures in the RA (e, arrowheads) and RV (g, arrowheads) of control, but not Ang1CKO embryos (f,h). (i–l; Note:
for the experiment presented in i–l, both ‘control’ and ‘Ang1CKO’ mice contained the EphB4 tau-lacZ knockin allele; see Results.) EphB4-lacZ-positive
signals in the hearts of control and Ang1CKO embryos at E13.0. EphB4-lacZ-positive subepicardial coronary veins were observed in control (i,j, arrowhead),
but not Ang1CKO embryos (k,l, arrowhead). EphB4-lacZ-positive signals were also detected in the endocardial endothelium in both control and Ang1CKO
embryos. (m–p) Expression patterns of COUP-TFII in the hearts at E13.5. COUP-TFII-positive subepicardial coronary veins were observed in control
(m,n, arrowhead), but not in Ang1CKO embryos (o,p, arrowhead). (q–s) Quantification of the number of subepicardial APJ (q, E13.5), EphB4-lacZ (r, E13.0)
and COUP-TFII (s, E13.5) -positive vessels in the transverse section including inflow-tract of ventricle (n¼ 3). (r) The number of the EphB4-positive
vessels especially with vessel-like structures or with red blood cells were quantified. Scale bars, 100mm in a–h; 300mm in i,k,m,o; 25mm in j,l; and 75 mm
in n,p. RA, right atrium; RV, right ventricle. Values are shown as means±s.e.m. for three separate experiments. Student’s t-test was used to analyse
differences. **Po0.01 compared with control.
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Ang1CKO embryos show no defects in coronary artery
formation. Next, we examined the effect of cardiomyocyte-spe-
cific Ang1 deletion on the formation of coronary arteries. Since
the coronary arteries penetrate the aorta at E13.5 (ref. 1), we
performed coronary angiography in E13.5 embryos using an ink
injection technique (see Methods)26. The results revealed that
there was no significant difference in coronary artery formation
between the control and Ang1CKO embryos (Fig. 3a–d).
To confirm the expression of arterial endothelial marker
EphrinB2 in the Ang1CKO embryos, we created Ang1flox/flox;
a-MHC-Cre(þ ); EphrinB2 tau-lacZ(þ ) mice by crossing
Ang1þ /flox; a-MHC-Cre-TG mice with EphrinB2 tau-lacZ
knockin mice, which express the lacZ reporter gene in arterial
ECs27. EphrinB2-lacZ-positive signals were comparably observed
in the intramyocardial layers of control and Ang1CKO embryos
at E13.0 (Fig. 3e–h). The number of EphrinB2-lacZ-positive
vessels in Ang1CKO embryos was almost similar to that in
control embryos (Fig. 3i). These findings suggest that
cardiomyocyte-specific deletion of Ang1 did not affect the
formation of the intramyocardial coronary arteries.
Myocardial deletion of Ang1 reduces venous marker expres-
sion. To confirm the defect in coronary vein formation in
Ang1CKO embryos quantitatively, we examined the expression
levels of venous marker genes including APJ, Ephb4 and COUP-
TFII28. The expression levels of these mRNAs were significantly
reduced in the hearts of Ang1CKO embryos compared with those
of controls (Fig. 4a–c). In contrast, the expression levels of arterial
marker genes such as Efnb2, neuropilin-1 (Nrp1), Delta-like 4
(Dll4), hairy and enhancer of split 1 (Hes1), activin receptor-like
kinase 1 (Acvrl1) and Notch1 were not significantly affected in the
hearts of Ang1CKO embryos compared with those of controls
(Fig. 4d–i). These data indicate that myocardial Ang1 is
specifically involved in the formation of coronary veins, but not
coronary arteries.
Ang1CKO embryos display impaired development of myo-
cardium. Through the analysis of Ang1CKO embryos, we noticed
that Ang1CKO embryos display impaired development of the
hearts. The thicknesses of compact layers in Ang1CKO embryos
were significantly thinner by approximately 40% than those in
control embryos (Supplementary Fig. 4a–d). In addition,
Ang1CKO embryos displayed a mild defect in trabeculation
compared with control embryos (Supplementary Fig. 4a,b).
Therefore, we next performed immunostaining with anti-phos-
pho-histone H3 (pHH3) antibody. Ang1CKO embryos display
impaired proliferation of cardiomyocytes compared with control
embryos (Supplementary Fig. 4e–g). We previously reported that
NRG-1/ErbB signalling is essential for cardiac homeostasis
presumably in part via secretion of Ang1 from cardiomyocytes16.
NRG-1 is an EGF-family growth factor, which is essential for
myocardial growth and trabeculation through the activation of
ErbB receptors during embryogenesis29. Thus, we examined
whether myocardial deletion of Ang1 might affect the expression
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Figure 3 | Myocardial Ang1 is dispensable for coronary artery formation. (a–d) Coronary angiography by ink injection into the hearts of control (a,b) and
Ang1CKO embryos (c,d) at E13.5. (e–h; Note: for the experiment presented in e–h, both ‘control’ and ‘Ang1CKO’ mice contained the EphrinB2 tau-lacZ
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positive vessels in the transverse section including inflow-tract of ventricle from E13.5 (n¼ 3). Scale bars, 100mm in a–d; 300mm in e,g; and 50mm in f,h.
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used to analyse differences. NS, not significant.
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level of NRG-1 in the hearts. We found that the mRNA level of
Nrg-1 in the hearts of Ang1CKO embryos was significantly lower
than in those of control embryos (Supplementary Fig. 4h).
Therefore, the reduced myocardial growth of Ang1CKO embryos
might be partly attributed to the reduced expression of Nrg-1
gene in the hearts of Ang1CKO embryos. In addition, we also
found that the formation of interventricular septum was
significantly impaired in all Ang1CKO embryos compared with
control at E13.5-E14.0 presumably due to the impaired
myocardial growth (Fig. 3e,g, Supplementary Fig. 4a,b). Taken
together, these findings indicate that the embryonic lethality of
Agn1CKO embryos between E12.5 and E14.5 might be ascribed
to the combinatorial defects in both coronary vein formation and
myocardial growth.
Ang1 is predominantly expressed in the atria and ventricles.
We next examined the expression pattern of Ang1 in the
embryonic heart during coronary vessel formation. We generated
an Ang1-mCherry reporter mouse as described in Methods, since
commercial antibodies were not available to detect the endo-
genous expression of Ang1 in murine tissue. Immunostaining
with an anti-DsRed antibody in the cryosectioned samples of
Ang1-mCherry reporter mice demonstrated that Ang1 was
strongly expressed in the atria and ventricles to a similar extent at
E11.5 (Supplementary Fig. 5a). At E13.5, Ang1 expression was
confined to the atria and ventricular trabeculae (Supplementary
Fig. 5b).
We next evaluated the expression of Tie2 by X-gal staining
using Tie2-lacZ transgenic mice30. At E10.5, the strongest Tie2-
lacZ signal in the cardiovascular system of these mice was
detected in the SV (Fig. 5a,b). Tie2-lacZ signals were also
observed in the endocardial endothelium of the atria and
ventricles at E10.5, but were markedly weaker than those in the
SV (Fig. 5a,b), indicating that Ang1 may be involved in the
migration of Tie2-positive ECs of the SV toward the myocardium.
Myocardial Ang1 attracts Tie2-positive ECs from SV. Previous
study suggested that the ECs of the SV are one of the most
plausible candidate sources of coronary ECs9. In addition, Tie2
was most strongly expressed in the ECs of the SV at E10.5, when
the ECs of the SV begin to invade the atrium (Fig. 5a,b). Thus, we
hypothesized that myocardial Ang1 might attract the ECs of the
SV. Therefore, we examined whether myocardial Ang1 is indeed
responsible for the migration of ECs from the SV into the
ventricular myocardium by using a cardiac organ culture system
modified to enable the detection of Tie2-lacZ-positive ECs
migrating from the SV9,30. Developing hearts were isolated
from Tie2-lacZ transgenic mice, Ang1flox/flox (control) mice or
Ang1CKO mice at E10.5, after the proepicardium has spread over
the heart surface to form the epicardium but before any coronary
sprouts are present. Since Tie2-lacZ was expressed in the
endocardial endothelium of the embryonic heart, Tie2-lacZ
signals were detected throughout the embryonic heart when the
intact hearts were resected from Tie2-lacZ transgenic mice,
cultured for 72 h and stained with X-gal (Supplementary Fig. 6a).
On the contrary, no Tie2-lacZ-positive signals were detected
throughout the embryonic heart resected from wild-type
(control) embryos (Supplementary Fig. 6b). Therefore, the
hearts were dissected to separate the ventricles with their
epicardial covering (VþEpi) from the SV and atria (SVþA).
When the SVþA or VþEpi resected from Tie2-lacZ mice
were cultured separately for 72 h and stained with X-gal,
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Tie2-lacZ-positive signals were observed in the atria or ventricle
in a similar patchy fashion (Supplementary Fig. 6c,d).
The SVþA resected from Tie2-lacZ transgenic mice were
combined with the VþEpi resected from either control or
Ang1CKO mice, and then cultured for 72 h and stained with
X-gal to determine whether Tie2-lacZ-positive coronary vessels
had sprouted and migrated into the ventricles (Fig. 5). When the
SVþA resected from Tie2-lacZ mice was cultured with the Vþ
Epi of control mice, Tie2-lacZ-positive coronary vessels were
detected on the VþEpi (Fig. 5c,e; 7 of 11, 64%). However, when
the SVþA resected from Tie2-lacZ mice were cultured with the
Vþ Epi of Ang1CKO mice, the formation of Tie2-lacZ-positive
coronary vessels on the VþEpi was disturbed (Fig. 5d,f; 2 of 7,
29%). Consistent with these findings, the mean migratory
distance from the border between the atrium and ventricle to
the leading edge of the Tie2-positive ECs in the ventricle was
significantly longer in the culture of the Tie2-lacZ atrium with the
control ventricle than in that of the Tie2-lacZ atrium with the
Ang1CKO ventricle (Fig. 5g). Collectively, these experiments
suggest that Ang1 derived from the ventricular myocardium
might be involved in attraction of the Tie2-positive ECs from the
SV towards the ventricular myocardium.
The ECs of SV consist of APJ-positive and APJ-negative cells.
The SV is considered one of the most plausible sites of origin for
coronary vein ECs9,11. Therefore, we examined the expression
patterns of several EC markers in the SV. We performed double
immunostaining with anti-CD31 and anti-Tie2 antibodies.
Consistent with the results obtained from the X-gal staining of
Tie2-lacZ transgenic mice, all of the CD31-positive ECs in the
SV were positive for Tie2 in control embryos (Fig. 6a–c).
Furthermore, the expression pattern of Tie2 in Ang1CKO and
control embryos was quite similar (Fig. 6d–f), suggesting that
Tie2 is uniformly expressed in the ECs of the SV in both control
and Ang1CKO embryos. In addition, VEGFR2 immunostaining
colocalized with that of Tie2 in the SV of control and Ang1CKO
embryos (Supplementary Fig. 7a–f), indicating that VEGFR2 is
also uniformly expressed in the ECs of the SV. We also performed
X-gal staining of EphrinB2-lacZ knockin mice at E10.5 and
confirmed that the arterial endothelial marker EphrinB2 is not
expressed in the SV at E10.5 (Supplementary Fig. 7g–i). These
data suggest that CD31, Tie2 and VEGFR2 are all expressed
uniformly in the ECs of the SV.
In clear contrast, APJ was not uniformly expressed in the ECs
of the SV in either control or Ang1CKO embryos (Fig. 6g–l). This
finding indicates that the ECs in the SV at E10.5 consist of two
populations, namely the APJ-positive and APJ-negative ECs
(Fig. 6m).
The APJ-negative ECs migrate from SV into myocardium. We
next addressed the characteristics of the CD31-positive ECs
migrating from the SV into the atrium. Intriguingly, APJ-negative
ECs were exclusively detected in the coronary sprouts in the atria
of both control and Ang1CKO embryos at E11.5 (Fig. 6n–t). We
also confirmed that APJ-positive vessels were not detected in the
atrium of either control or Ang1CKO embryos at E11.5 by
whole-mount immunostaining with an anti-APJ antibody
(Supplementary Fig. 7j–m). However, at E12.5, APJ was expressed
in the atrial CD31-positive vessels in control embryos, but not in
Ang1CKO embryos (Fig. 6u–z, arrowheads). These data are
consistent with the data obtained from whole-mount immunos-
taining with the anti-APJ antibody at E13.0 (Fig. 2a,b). Taken
together, these findings suggest that Ang1 secreted from the atrial
myocardium promotes the upregulation of APJ and the venous
differentiation of ECs sprouting from the SV into the atrium of
control embryos (Fig. 6aa).
The expression of APJ in the vessels migrating from the atrium
into the ventricles was not detected in control or Ang1CKO
embryos at E12.5 (Fig. 6u–z, arrow). These data indicate that the
APJ-negative ECs migrate from the SV into the atrium at E11.5
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(Fig. 6t) and subsequently into the ventricle at E12.5, followed by
the appearance of APJ-positive, mature ECs in the atrium
(Fig. 6aa). Whole-mount immunostaining analysis of the wild-
type embryos revealed the emergence of APJ-positive vessels on
the ventricular surface on and after E13.5 (Supplementary
Fig. 2e–h), one day later than the emergence of CD31-positive
vessels (Supplementary Fig. 2a–d). These findings indicate that
the APJ-negative ECs precede the appearance of the APJ-positive
mature venous ECs in the ventricle.
The APJ-negative ECs were also detected in the ventricles of
wild-type embryos both at E12.5 (Fig. 7a–c, j, arrows in area 2)
and E13.5 (Fig. 7d–f, k, arrows in area 4). However, at E14.5, the
APJ-negative subepicardial ECs could not be detected at the
forefront of the invading vessels in the wild-type ventricles
(Fig. 7g–i, l). These data suggest that immature APJ-negative ECs
in the ventricles may differentiate into APJ-positive ECs at E14.5
in response to myocardial Ang1 (Fig. 7l).
Consistent with the whole-mount immunostaining with anti-
APJ antibody results (Fig. 2c,d,g,h), APJ-positive ECs were
observed in the basal subepicardial layers of both the right and
left ventricles of control embryos, but not in those of Ang1CKO
embryos at E13.5 (Supplementary Fig. 8a–g). Taken together,
these data suggest that the APJ-negative ECs migrate from the SV
into the atrium and subsequently into the ventricle at the
forefront of the invading vessels and precede the appearance of
APJ-positive ECs. The emergence of APJ-positive ECs occurs one
day later in the atria and ventricles and requires the presence of
myocardial Ang1.
In addition, we examined the proliferation of the subepicardial
CD31-positive ECs in the hearts of both control and Ang1CKO
embryos. Since we observed the invasion of CD31-positive
subepicardial ECs from atria into the basal region of the ventricles
in both control and Ang1CKO embryos (Fig. 1e,f), we examined
the proliferation of CD31-positive subepicardial ECs in the
ventricles of control and Ang1CKO embryos. The number of
subepicardial ECs double-positive for pHH3 and CD31 in the
ventricles of Ang1CKO embryos was 44% smaller than that in
control embryos (Supplementary Fig. 9a–c), suggesting that
myocardial deletion of Ang1 led to the impaired proliferation of
CD31-positive subepicardial ECs.
We also examined the expression levels of VEGF-A and
VEGFR2 mRNAs in the hearts. They were almost comparable
between control and Ang1CKO embryos (Supplementary
Fig. 9d,e), indicating that the CD31-positive APJ-negative
immature ECs in the subepicardial region of Ang1CKO hearts
might be recruited from SV partly by the action of myocardium-
derived VEGF-A. These findings suggest that myocardial Ang1
contributes not only to the migration but also to the proliferation
of subepicardial immature ECs.
Ang1 promotes venous differentiation of the immature ECs.
The finding that APJ-negative ECs of the SV expressed APJ one
or two days after migrating into the myocardium in control mice,
but not in Ang1CKO mice suggested that Ang1 might be critically
involved in the venous differentiation of immature ECs in the
heart. Therefore, we examined the effect of Ang1 on arterial–
venous specification using the Flk1-positive endothelial pro-
genitor cells derived from embryonic stem (ES) cells (Flk1þ
cells)28,31. Since the ECs that invade the atrium from the SV do
not express either the arterial marker EphrinB2 or the venous
marker APJ, we reasoned that the Flk1þ cells, which are double-
negative for these markers, would be suitable for analysing the
effects of Ang1 on the arterial–venous specification of the ECs.
Treatment with VEGF and 8-bromo-cyclic-AMP (cAMP)
upregulated the expression of the arterial marker EphrinB2 in
Flk1þ cells, as reported previously (Supplementary Fig. 10a,b)31.
Next, we examined the additive effects of treatment with cartilage
oligomeric matrix protein (COMP)-Ang1, a potent variant of
Ang1 (ref. 32), VEGF and cAMP on Flk1þ cells. Interestingly,
treatment with COMP-Ang1 inhibited the induction of EphrinB2
by VEGF and cAMP (Supplementary Fig. 10c). qRT–PCR
analysis also demonstrated that co-treatment with COMP-Ang1
counteracted the upregulation of Efnb2 mRNA by VEGF and
cAMP (Supplementary Fig. 10d).
In contrast, immunocytochemical analysis revealed that the
transcription factor COUP-TFII, which is postulated to have a
key role in venous differentiation24,25, was significantly
upregulated in Flk1þ cells when stimulated with VEGF, cAMP
and COMP-Ang1 (Fig. 8a–c). Consistent with these findings,
qRT–PCR analysis revealed that co-stimulation with VEGF,
cAMP and COMP-Ang1 upregulated the expression level of
COUP-TFII in Flk1þ cells, although neither the co-stimulation
with VEGF and cAMP nor that with VEGF and Ang1
upregulated the expression level of COUP-TFII (Fig. 8d).
Interestingly, co-stimulation with VEGF and COMP-Ang1 did
upregulate the expression level of APJ mRNA in Flk1þ cells,
whereas VEGF or co-stimulation with VEGF and cAMP did not
significantly affect the expression level of APJ, indicating that APJ
upregulation may be a prerequisite for the induction of COUP-
TFII in Flk1þ cells (Fig. 8e).
In addition, we also examined the requirement of Tie2
receptor for the effect of Ang1 on the venous differentiation
of Flk1-positive endothelial progenitor cells by siRNA-
mediated knockdown of Tie2. We first confirmed that the
expression level of Tie2 protein was significantly reduced by
approximately 80% in the immature Flk1-positive endothelial
progenitor cells (Supplementary Fig. 11a). We found that
siRNA-mediated knockdown of Tie2 significantly blunted
Ang1-dependent upregulation of COUP-TFII and APJ
mRNAs (Supplementary Fig. 11b,c). These findings suggest that
Tie2 activation is required for the Ang1-dependent venous
differentiation of the immature Flk1-positive endothelial
progenitor cells. Collectively, these data suggest that
Ang1/Tie2 signalling promotes the venous differentiation of
Figure 6 | APJ-negative ECs sprout off from the SV and migrate into the embryonic atria and ventricles. (a–f) Sagittal section through the SV of
control (a–c) and Ang1CKO embryos (d–f) at E10.5 immunostained for CD31 (green) and Tie2 (red). CD31 and Tie2 were uniformly expressed in the ECs of
the SV (arrowheads). (g–l) Sagittal section through the SV of control (g–i) and Ang1CKO embryos (j–l) at E10.5 immunostained for CD31 (green) and
APJ (red). APJ-negative ECs were detected among the CD31-positive ECs in both control and Ang1CKO embryos (arrows). ECs in the SV expressing
both CD31 and APJ were similarly observed in control and Ang1CKO embryos (arrowheads). (m) Schematic illustrations of the SV at E10.5 showing that
the ECs were heterogeneous for APJ expression. (n–s) Sagittal sections through the right atrium (RA) of control (n–p) and Ang1CKO embryos (q–s) at
E11.5 immunostained for CD31 (green) and APJ (red). (t) Schematic illustrations of the RA at E11.5 showing that all of the invading ECs were negative
for APJ in both control and Ang1CKO embryos. (u–z) Sagittal section through the RA and right ventricle (RV) of control (u–w) and Ang1CKO embryos
(x–z) at E12.5 immunostained for CD31 (green) and APJ (red). The CD31-positive ECs invading the RV did not express APJ in either control or Ang1CKO
embryos (arrow). In contrast, APJ was expressed in all of the CD31-positive ECs in the RA of control, but not Ang1CKO embryos (arrowheads). (aa)
Schematic illustration of the RA and RV at E12.5 summarizing the expression of APJ. Blue line, APJ-positive ECs; black line, APJ-negative ECs. Scale bars,
50mm. RA, right atrium; RV, right ventricle; SV, sinus venosus.
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immature vascular progenitor Flk1þ cells via the upregulation
of COUP-TFII and APJ. Since the growth factor(s)
responsible for regulating COUP-TFII have not been identified
to date, Ang1 might be a promising candidate factor for
promoting the venous differentiation of immature ECs in the
developing heart.
Discussion
These findings demonstrate that Ang1 is essential for coronary
vein formation in developing heart (Fig. 9a,b). Ang1CKO mice
displayed significant defects in the migration of the APJ-negative
immature ECs from the SV into the myocardium, the prolifera-
tion and the venous differentiation of the immature ECs.
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Together, Ang1CKO mice exhibited defective formation of
subepicardial coronary veins. In addition, Ang1 in combination
with VEGF and cAMP induced the venous differentiation of
Flk1þ vascular progenitor cells, whereas the combination of
VEGF and cAMP promoted arterial differentiation of the Flk1þ
vascular progenitor cells. To our knowledge, this is the first report
describing the growth factor responsible for the venous
differentiation of immature ECs.
The origin of coronary ECs has been a long-lasting question.
Ang1CKO mice displayed specific defects in the development of
APJ-, EphB4-, COUP-TFII-positive coronary veins (Fig. 2);
however, they showed no significant defects in coronary artery
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Figure 7 | APJ-negative ECs precede APJ-positive ECs on the ventricle surface. Sagittal sections through the RA and RV of wild-type embryos at E12.5
(a–c), E13.5 (d–f), E14.5 (g–i) immunostained for CD31 (green) and APJ (red). At E12.5 and E13.5, the APJ-negative (immature) ECs migrated at the
forefront of the sprouting subepicardial coronary vessels (arrows in a–c area 2, d–f area 4) and preceded the appearance of the APJ-positive (mature) ECs
(arrowheads). At E14.5, all of the subepicardial ECs were double-positive for CD31 and APJ (arrowheads in g–i). (j–l) Schematic illustration of the SV, RA
and RV at E12.5 (j), E13.5 (k) and E14.5 (l). Blue line, APJ-positive ECs; black line, APJ-negative ECs. Scale bars, 200mm (upper panels in a–i); 50mm
(insets). RA, right atrium; RV, right ventricle; SV, sinus venosus.
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formation as evaluated by either coronary arteriogram with ink
injection or detection of EphrinB2-lacZ-positive coronary arteries
(Fig. 3). Wu et al.11 recently reported that both cardiomyocyte-
specific VEGF-A KO mice and endocardium-specific VEGFR2
KO mice exhibit specific defects in coronary artery formation, but
not in coronary vein formation. They reported that the ECs of the
ventricular endocardium, but not those of the SV, generate the
endothelium of coronary arteries. Their findings complement our
findings obtained with Ang1CKO mice, suggesting that the
formation of coronary arteries and veins might be distinctly
regulated by VEGF-A/VEGFR2 signalling and Ang1/Tie2
signalling, respectively.
On the other hand, Red-Horse et al.9 reported that the ECs of
the SV are the common originators of both coronary arteries and
veins, using clonal analysis, crossing VE-Cadherin-Cre(ER)T2
mice with either Rosa-lacZ or multicolour Cre recombination
reporters, and organ culture experiments combining the SV and
atrium from Apelin-nLacZ-reporter mice with ventricles from
wild-type mice. We also performed organ culture experiments
combining the SV and atrium from Tie2-lacZ reporter mice with
the ventricles and epicardium from either wild-type or Ang1CKO
mice. These experiments suggested that Ang1 derived from the
ventricular myocardium might attract the Tie2-positive ECs from
the SV towards the ventricular myocardium presumably via
promotion of migration and proliferation of the immature ECs
(Fig. 5). Since we could not address the arterial–venous identity of
the Tie2-positive ECs migrating into the wild-type ventricles due
to the loss of the antigenicity in the organ culture samples, we
cannot exclude the possibility that the ECs of SV might partly
contribute to the formation of coronary arteries independent of
the action of myocardial Ang1. So, the issues on the origin of the
coronary arteries should be clarified in the future.
Katz et al.10 recently reported that the Semaphorin3D/Scleraxis
lineage-traced proepicardial cells, which migrate via SV
endothelium into the myocardium and/or transiently contribute
to the endocardium, differentiate into the coronary ECs. This
finding indicates that the proepicardial cells as well as the SV ECs
might be one candidate source for coronary vein ECs. Since there
have been no appropriate reporter mice to specifically trace the
lineage of the SV ECs to date, we should determine the origins of
the coronary veins through identifying the marker genes
specifically expressed in the ECs of the SV in the future.
Ang1 is reported to enhance the migration of the vascular ECs
in cooperation with VEGF33. Consistent with this finding,
Ang1CKO mice showed impaired migration of subepicardial
immature APJ-negative ECs compared with control mice (Fig. 1
and Supplementary Fig. 2). Since the coronary artery formation
was almost intact in Ang1CKO mice (Fig. 3), the myocardium-
derived VEGF-dependent signalling and migration of ECs
appeared to be preserved in these mice. These data indicate
that Ang1 might regulate the migration of immature ECs from
the SV into the myocardium in cooperation with VEGF derived
from the myocardium.
On the other hand, we also found that Ang1CKO embryos
showed impaired proliferation of subepicardial ECs compared
with control embryos (Supplementary Fig. 9a–c). Previous studies
revealed that Ang1 exerts opposing effects such as proliferation
and stabilization of the cell–cell contact of the ECs depending on
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Figure 8 | Ang1 enhances venous differentiation of Flk1þ immature endothelial progenitor cells synergistically with VEGF. (a–c) The venous marker
protein COUP-TFII was upregulated in vascular progenitor Flk1þ cells by the addition of COMP-Ang1 to VEGF and cAMP. Flk1þ cells were immunostained
with anti-CD31 antibody (red) and anti-COUP-TFII antibody (green). Nuclei were stained with DAPI (blue). (d–e) Quantitative expression analysis of the
venous marker genes COUP-TFII and APJ in the Flk1þ cells (normalized to GAPDH mRNA; n¼ 3). (d) The expression of COUP-TFII mRNA was increased
exclusively by the combined treatment with VEGF, cAMP and COMP-Ang1. (e) The expression of APJ mRNA in the Flk1þ cells was significantly
upregulated by stimulation with VEGF and Ang1 compared with treatment with VEGF alone. APJ mRNA was further upregulated by the addition of COMP-
Ang1 to VEGF and cAMP. The results were expressed as relative intensity over cells treated with VEGF. Scale bars, 50mm. Values are shown as
means±s.e.m. for three separate experiments. One-way analysis of variance was used to compare differences. *Po0.05, **Po0.01, ***Po0.001 for the
indicated groups.
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the cellular contexts34,35. While Ang1 can bridge Tie2 at cell–cell
contacts and mediates trans-association of Tie2 in the presence of
cell–cell contacts, extracellular matrix-bound Ang1 locates Tie2 at
cell–substratum contacts in isolated cells34. Of note, Tie2
activated at cell–cell or cell–substratum contacts leads to
preferential activation of Akt and Erk, respectively34,35,
suggesting that Ang1 can evoke distinct cellular responses in
the ECs according to the cellular environment. Taken together,
myocardial Ang1 might contribute to the formation of coronary
veins by promoting both proliferation and migration of the
immature ECs derived from SV.
The ECs of the SV were found to be heterogeneous, consisting
of both APJ-positive and -negative cells. Among the ECs in the
SV, only the APJ-negative ECs were found to migrate into the
atrium and ventricles. Furthermore, all of the atrial subepicardial
ECs were APJ-positive following 1 day of exposure to Ang1
expressed in the atrial myocardium (Fig. 6). Thus, the APJ-
positive ECs appeared to be produced through differentiation of
the APJ-negative ECs by the action of myocardial Ang1.
Our findings indicate that myocardial Ang1 has a critical role
in coronary vein formation by mediating the migration,
proliferation and venous differentiation of immature ECs in the
developing hearts. Elucidation of the molecular mechanisms
underlying Ang1-mediated venous differentiation will provide
insight into heart disease and tissue regeneration.
Methods
Animals. The targeting vector for creating Ang1flox allele was constructed by
inserting loxP/PGK-Neo-pA/loxP into exon 1 of the genomic Ang1 locus17. The
targeting vector was introduced into TT2 embryonic stem cells. The targeted
embryonic stem cell clones were injected into CD-1 8-cell stage embryos, and
the resultant male chimera mice were mated with C57BL/6 females to establish
germ line transmission. Ang1flox(neoþ ) mice were maintained in CBA/C57BL/6/
CD-1 mixed background. The neomycin cassette in Ang1flox(neoþ ) allele was
excised through crossing with CAG-FLPe transgenic mice in C57BL/6 background
(B6-Tg(CAG-FLPe)36)36. To create Ang1CKO mice, we crossed Ang1flox/flox mice
with a-MHC-Cre transgenic mice in a C57BL/6 background16,17. Tie2-lacZ
transgenic (FVB/N-Tg(TIE2-lacZ)182Sato/J) mice were purchased from the
Jackson Laboratory30. The EphB4 tau-lacZ knockin mice and EphrinB2 tau-lacZ
knockin mice were used for determination of the arterial–venous lineages of the
coronary ECs23,27. Enhanced green fluorescent protein (EGFP) reporter mice
(CAG-CAT-EGFP) were obtained from J. Miyazaki, Osaka University37. The Ang1-
mCherry gene construct was generated from a BAC clone (RP23-5J11) containing a
144-kb genomic fragment spanning the region upstream of the Ang1 locus. The
targeting vector used to modify BAC RP23-5J11 was designed to insert the
mCherry sequence into the first coding exon of the Ang1 gene. The 50 and 30
homology sequence, the mCherry gene, and the fragment including the poly A
sequence were cloned into PL453, which contained the neomycin-resistance
cassette flanked by Frt sites.
All animals were maintained in a virus-free facility on a 12-h light/12-h dark
cycle and fed a standard mouse diet. All experiments were carried out under the
guidelines of the Osaka University Committee for animal and recombinant DNA
experiments and were approved by the Osaka University Institutional Review
Board.
Genotyping of the animals. The PCR primers used for genotyping were as
follows: Ang1 flox: 50-CCGGATTCAACATGGGCAATGTGCC-30 , 50-CAGTCA
AAATGCCTAAGATAAAC-30 ; Cre: 50-ACATGTTCAGGGATCGCCAG-30,
50-TAACCAGTGAAACAGCATTGC-30; lacZ: 50-CAGACGATGGTGCAGGAT
AT-30 , 50-ATACAGCGCGTCGTGATTAG-30 ; Ang1-mCherry: 50-AGGACGGCG
AGTTCATCTAC-30 , 50-TGGTGTAGTCCTCGTTGTGG-30 ; EGFP: 50-AGCAA
GGGCGAGGAGCTGTT-30 , 50-GTAGGTCAGGGTGGTCACGA-30 .
Detection of b-galactosidase activity in embryonic tissues. Embryonic tissues
were fixed in 0.2% glutaraldehyde in phosphate-buffered saline (PBS) containing
5mM EGTA and 2mM MgCl2 at 4 C for 4 h, washed in washing buffer (2mM
MgCl2, 0.02% NP-40, 0.1% sodium deoxycholate in PBS) for 30min three times,
Arteries
ep myo
Arteries
E10.5 E11.5 E12.5 E13.5 E14.5
RA
RV
SV
RA
RV
SV
C
on
tr
ol
A
ng
1C
K
O
Ang1CKOControl
Immature
vein
Mature
veins
Figure 9 | Role of Ang1 on coronary vessel formation. (a) Working model of coronary vein formation. The upper panel shows a schematic illustration of
coronary vein formation in wild-type mice. The ECs in the SV at E10.5 consist of APJ-positive mature ECs (blue) and APJ-negative immature ECs
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cryoprotected with 30% sucrose, and frozen in OCT compound (Tissue Tek) and
cryosectioned. Samples were stained in X-gal staining buffer (5mM potassium
ferricyanide, 5mM potassium ferrocyanide, 1mg/ml X-gal in washing buffer) at
37 C.
Histological analysis. Dissected embryonic hearts were fixed in 4% paraf-
ormaldehyde (PFA)/PBS overnight at 4 C, embedded in paraffin and sectioned at
7 mm thickness. Hematoxylin/eosin staining was performed according to standard
procedures on the paraffin sections16.
Immunohistochemical analysis. The following antibodies were used: anti-CD31
(550274) and anti-VEGFR2 (550549) (BD Pharmingen), anti-Tie2 (sc-324, Santa
Cruz), anti-beta-galactosidase (NB100-2045, Novus Biologicals), anti-DsRed
(632496, Clontech), anti–phospho–Histone H3 (Ser10) (06-570, Merck Millipore).
The whole-mount immunohistochemistry of mouse embryos using anti-CD31
monoclonal (1:100) and anti-APJ antibodies (1:100) was performed38,39.
Embryonic hearts were dissected and fixed in 4% PFA/PBS overnight at 4 C.
Samples were washed in PBS, dehydrated in absolute methanol (MeOH) and stored
at  20 C until antibody staining. Embryonic hearts were incubated in Dent’s
bleach (MeOH: dimethyl sulfoxide: 30%H2O2, 4:1:1) for 3 h at room temperature
and washed with a series of descending MeOH/PBST (PBSþ 0.1% Triton-X)
concentrations (70%MeOH, 50%MeOH, PBST). Samples were blocked in 2%
skimmed milk for 1 h and incubated with primary antibodies overnight at 4 C.
Next day samples were washed three times for 1 h with PBST and incubated with
secondary antibodies overnight at 4 C. Finally samples were washed three times
for 1 h with PBST and applied with DAB (Invitrogen) at room temperature. When
necessary, 7 mm sections were cut from paraffin-embedded whole-mounts.
For frozen section immunohistochemistry, embryos or isolated embryonic
hearts were fixed for 4 h to overnight in 4% PFA/PBS. Fixed embryos or hearts
were soaked in a 15–30% sucrose gradient before being embedded in OCT (Tissue
Tek) for frozen sections and cut by cryosectioning (10 mm). Sections were
rehydrated in PBS, incubated in blocking solution containing either 5% normal
goat serum, 1% bovine serum albumin and 2% skim milk or 10% normal goat
serum in PBST for 1 h and then incubated with primary antibodies (CD31 1:300,
Tie2 1:200, APJ 1:300, VEGFR2 1:100, Beta-galactosidase 1:4000, DsRed 1:1000,
phospho Historne H3 1:100) in Can Get Signal immunostain (TOYOBO, NKB-
601) overnight at 4 C. Sections were then washed in PBST and incubated with
fluorescent-conjugated (Invitrogen; Alexa Fluor 488 and 546) or horseradish
peroxidase (HRP)-coupled (Cell Signaling Technology (7074), 1:200) secondary
antibodies for 30min to 1 h at room temperature. Images were acquired with a
microscope (Keyence, BZ-9000).
Whole-mount in situ hybridization. Embryos were fixed in 4% PFA/PBS over-
night at 4 C and stored in 100% MeOH at  20 C until hybridization. The Ang1
antisense probe was generated from mouse Ang1 cDNA18. Whole-mount in situ
hybridization was performed at 70 C for 18 h for each sample40. The detection was
performed with alkaline phosphatase-coupled anti-digoxygenin antibody
(Boehringer Ingerheim) overnight at 4 C. After washing, the chromogenic reaction
was performed with NBT–BCIP substrate (Promega). Photographs were captured
with a stereomicroscope (Olympus, SZX12).
In situ hybridization on frozen sections. Embryos were fixed overnight in 4%
PFA/PBS. Fixed embryos were soaked in a 15–30% sucrose gradient before being
embedded in OCT (Tissue Tek) for frozen sections (10 mm). Sections were rehy-
drated in PBS. A 994 bp long in situ probe was generated of the mouse COUP-TFII
gene (Forward: CGGAATTCTCAACTGCCACTCGTACCT, Reverse: CCAC-
TAGTGCTTTCCACATGGGCTACAT). In situ hybridization was performed in a
similar method to whole-mount in situ hybridization40. Hybridized DIG-RNA
probes were detected with alkaline phosphatase-coupled anti-digoxygenin antibody
overnight at 4 C. Photographs were captured with BZ-9000 (KEYENCE).
Coronary arteriogram of murine embryos. Hearts were resected from embryos
and placed in heparinized PBS. Ink (Kiwa-guro; Sailor) was injected in a retrograde
fashion from the ascending aorta using a glass micropipette and fixed in 4% PFA/
PBS26. Photographs were captured using a stereomicroscope (Olympus, SZX12).
Quantitative real-time RT–PCR. Quantitative real-time RT–PCR was carried out
using the QuantiFast SYBRGreen RT–PCR kit (Qiagen)39. For each reaction, 80 ng
of total RNA was transcribed for 10min at 50 C followed by a denaturing step at
95 C for 5min and 40 cycles of 10 s at 95 C and 30 s at 60 C. Fluorescence data
were collected and analysed using ABI PRISM 7900HT. The primers used for
amplification of total RNA from murine hearts were as follows: GAPDH: 50-TC
TCCACACCTATGGTGCAA-30 , 50-CAAGAAACAGGGGAGCTGAG-30; Ang1
50-GCAGCCATAGCAATGCCAGAGGT-30 , 50-TCCCATGGCAACTCACAAAA
CTCC-30; Efnb2: 50-TGTTGGGGACTTTTGATGGT-30: 50-GTCCACTTTGGG
GCAAATAA-30 ; Ephb4: 50-CTGGATGGAGAACCCCTACA-30 , 50-CCAGGTA
GAAGCCAGCTTTG-30; COUP-TFII: 50-GCAAGTGGAGAAGCTCAAGG-30 ,
50-TTCCAAAGCACACTGGGACT-30 ; Notch1: 50-TGTTGTGCTCCTGAAG
AACG-30 , 50-TCCATGTGATCCGTGATGTC-30 ; Dll4: 50-TGCCTGGGAAGT
ATCCTCAC-30 , 50-GTGGCAATCACACACTCGTT-30; Acvrl1: 50-CCAATGACC
CCAGTTTTGAG-30, 50-TTGGGGTACCAGCACTCTCT-30 ; Hes1: 50-ATCATG
GAGAAGAGGCGAAG-30 , 50-CGGAGGTGCTTCACAGTCAT-30 ; Nrp1: 50-CC
GGAACCCTACCAGAGAAT-30 , 50-AAGGTGCAATCTTCCCACAG-30 ; APJ:
50-CAGTCTGAATGCGACTACGC-30, 50-CCATGACAGGCACAGCTAGA-30.
Organ cultures. Heart cultures were carried out according to the previous report9.
In brief, embryonic hearts were dissected from wild-type, Tie2-lacZ or Ang1CKO
embryos, and the atria and attached sinus venosus (SV/A) were then dissected from
the ventricles. The SV/A tissues from the Tie2-lacZ embryos were placed adjacent
to the ventricles of either wild-type or Ang1CKO embryos at the position where the
original SV/A was removed. The explants were cultured dorsal side up at the air–
liquid interface on 8-mm Millicell Cell Culture Insert Filters (Merck Millipore).
Cultures were maintained at 37 C and 5% CO2 in DMEM with 2 mgml 1 heparin,
100Uml 1 penicillin, 100 mgml 1 streptomycin, 2mM L-glutamine and 10%
fetal bovine serum. After 72 h, explants were fixed with 4% PFA/PBS and subjected
to whole-mount X-gal staining. Some stained explants were embedded in paraffin
and then sectioned.
Cell culture and differentiation of embryonic stem cells. ES cell lines EStTA-
ROSA, and various EStTA derivatives were maintained with Glasgow’s MEM
(GMEM; Invitrogen) containing 1 10 4M 2-mercaptoethanol (Invitrogen), 10%
knockout serum replacement (KSR; Invitrogen), 1% fetal calf serum (FCS; SAFC
Biosciences), 1mM sodium pyruvate (Sigma), 1% non-essential amino acids
solution (Invitrogen) and 2 103Uml 1 leukaemia inhibitory factor (Merck
Millipore). Differentiation was induced in these ES cell lines using differentiation
medium (DM) consisting of minimum essential medium alpha (Invitrogen) sup-
plemented with 10% FCS (Invitrogen) and 5 10 5M 2-mercaptoethanol31,41. In
brief, undifferentiated ES cells were cultured on gelatin-coated dishes without
leukaemia inhibitory factor at a density of 0.75–103 cells per cm2 for 4.5 days.
Cultured cells were harvested and subjected to magnetic cell sorting (MACS)
purification. Purified Flk1þ cells were then plated onto gelatin-coated dishes at a
density of 0.75–104 cells per cm2 in DM. After 3 days, induced ECs were examined
by immunocytochemistry and FACS analysis. Human VEGF165 (WAKO,
50 mgml 1) and 8-bromoadenosine-30 , 50-cyclic monophosphate sodium salt
(8-bromo-cAMP; Nacalai, 0.5mM) were added to the Flk1þ cell culture. COMP-
Ang1 was added to the Flk1þ cell culture at the concentration of 100 ngml 1
(ref. 32).
Stealth siRNAs targeting murine Tie2 gene were purchased from Invitrogen
(MSS211290, MSS211291, MSS278161). Cells were transfected with mixed three
siRNAs (total 50 nM) 12 h before Flk1þ cell purification using Lipofectamine
RNAiMAX reagent (Invitrogen) according to the manufacturer’s instructions.
Furthermore, Flk1þ cells were plated and simultaneously transfected with mixed
siRNAs (total 20 nM).
Immunocytochemical analysis of Flk1þ cells. The cultured ECs were immu-
nostained according to the previous report41. Briefly, for double-fluorescence
staining of COUP-TFII and CD31, ECs were fixed with 4% PFA/PBS. Fixed culture
slides were incubated with anti-COUP-TFII antibody (H7147, Perseus Proteomics)
and anti-CD31 (550274, BD Pharmingen). Culture slides were then washed in
PBST and incubated with fluorescent-conjugated secondary antibodies (Invitrogen;
Alexa Fluor 488 and 546). For double-fluorescence staining of EphrinB2 and CD31,
ECs were fixed with 5% dimethyl sulfoxide/MeOH. Fixed culture slides were
incubated with EphB4-human immunoglobulin (Ig) Fc portion chimeric protein
(EphB4-Fc; R&D Systems) followed by human IgG Fc peroxidase-conjugated goat
IgG fraction (ICN Biomedicals). The TSA biotin system (PerkinElmer) was used to
amplify the signal for EphB4-Fc staining. EphrinB2-positive cells were visualized
with streptavidin/Alexa Fluor 488 conjugate (Invitrogen). CD31-positive cells were
stained with PE-conjugated mAb for CD31.
Statistical analysis. All data were expressed as means±s.e.m. Differences among
multiple groups were compared by one-way analysis of variance. Student’s t-test
was used to analyse differences between two groups. A value of Po0.05 was
considered as statistically significant.
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